The optimal management of asymptomatic subjects at intermediate risk of coronary artery disease (CAD) is often uncertain. Re-stratification to a high-or low-risk category may enable optimization of preventative strategies. Coronary computed tomographic angiography (CCTA) enables a minimally invasive assessment of coronary artery plaque quantity and composition. Non-calcified plaque by CCTA is lipid-rich and more vulnerable to rupture and resultant acute coronary syndromes. The purpose of this study was to determine whether novel approaches to CAD risk stratification, such as plasma lipid profiling, may predict non-calcified plaque burden in intermediate risk subjects.
Introduction
Coronary artery disease (CAD) remains a major cause of mortality in the developed world. Advances in acute therapy for myocardial infarction (MI) have improved outcomes in those patients who survive to hospital admission; however, nearly half of all CAD-related deaths occur suddenly and unexpectedly, outside of the hospital. 1 Because there are no antecedent symptoms in up to two-thirds of cases of unexpected cardiac death, 2 a major focus of treatment at a population level is that of reducing the risk of future MI in those believed to be at higher risk. Reductions in mortality attributable to CAD are largely explained by improved cardiovascular risk factor control, principally smoking cessation along with an improved treatment of systemic hypertension and dyslipidaemia, and medical therapies such as aspirin. 3 Currently, a preventative strategy consisting of aggressive risk factor control along with aspirin therapy is recommended for patients with known symptomatic CAD and for asymptomatic patients who are classified as high risk according to traditional cardiovascular risk factor measurements, 4 such as the Framingham risk score. 5, 6 Despite the availability of effective preventive therapies, we still cannot accurately identify most patients who subsequently experience MI. Indeed, at the time of their first MI, up to 75% of patients would not have qualified for preventive therapy for CAD on the basis of their premorbid clinical history or risk factor profile. 3 Furthermore, while there is widespread consensus that patients deemed at low risk are best managed with lifestyle measures alone, many patients are classified as intermediate risk, leading to uncertainty regarding the optimal management approach and resultant heterogeneity in the use of aspirin and lipid-modifying medications. The ability to re-stratify intermediate risk patients as either low or high risk would confer important benefits. More aggressive medical therapy could be recommended for those re-stratified into the highrisk group, with expected improved clinical outcomes. Conversely, patients re-stratified as low risk could be managed with a more conservative approach, based predominantly on lifestyle factors, with likely reductions in pharmacotherapy-related costs and adverse effects. Several ancillary methods to enhance CAD risk stratification have been proposed, including high-sensitivity C-reactive protein (hs-CRP), 3, 7, 8 carotid intima-media thickness (CIMT), 9, 10 and aortic pulse wave velocity (PWV). 11, 12 Because lipids play a fundamental role in the formation, and subsequent disruption, of coronary atherosclerotic plaque, certain lipid species may also be useful markers of CAD. Plasma lipid profiling, a novel and rapid approach to plasma lipidomic analysis, has already been shown to discriminate between patients with stable and unstable CAD. 13 While the relationship of these surrogate markers to the presence of coronary artery plaque has been evaluated by invasive angiography, 14 -16 studies have been heavily biased towards symptomatic patients. Coronary computed tomographic angiography (CCTA) now permits minimally invasive enhanced characterization of CAD. For example, the identification of low-density, non-calcified plaque by CCTA has been associated with an increased risk of future acute coronary syndromes. 17, 18 To our knowledge, non-calcified coronary artery plaque has not previously been characterized in asymptomatic subjects at intermediate risk of CAD.
In the present study, we sought to prospectively evaluate coronary artery plaque with CCTA in a cohort of asymptomatic subjects who are classified as intermediate risk of CAD using traditional risk factors, and to determine whether plasma lipid profiling and other ancillary markers of CAD can predict plaque burden and plaque composition in these subjects.
Methods

Patient selection
All research was performed at the Alfred Hospital, Melbourne, Australia. Subjects were identified from an integrated database registry managed by the Baker IDI Heart and Diabetes Institute in Melbourne, Australia. This database contains prospectively recorded clinical information of over 20 000 volunteers, including their age, gender, and cardiovascular risk profile at the time of registration. A cohort of asymptomatic subjects were identified as being at intermediate risk of CAD, defined using the Framingham cardiovascular risk assessment tool as having an estimated 10 -20% 10-year risk of MI or coronary death. 6 Eligible subjects were contacted and invited to participate in the study. Exclusion criteria included previously documented CAD; symptoms suggestive of CAD; diabetes mellitus; chronic atrial fibrillation; contraindications to CCTA, including previous allergic reaction to iodinated contrast; and significant renal dysfunction (estimated glomerular filtration rate ,30 mL/min/1.73 m 2 ).
Informed consent was obtained from all participants, and the study was conducted in accordance with the Alfred Hospital Ethics Committee's guidelines.
CCTA protocol
All subjects underwent CCTA on a dedicated 64-slice CT scanner (Lightspeed VCT, GE Healthcare, USA). One hour prior to CCTA, subjects with resting heart rates .65 bpm were administered 50 or 100 mg metoprolol orally to achieve a resting heart rate of ≤60 bpm. Additionally, subjects with resting heart rates .60 bpm immediately prior to CCTA received up to 20 mg intravenous (IV) metoprolol. All subjects with a systolic blood pressure (SBP) of ≥100 mmHg received 0.4 mg nitroglycerin sublingually for coronary vasodilatation. Following initial scout images, a small timing bolus of 20 mL IV iodinated contrast (Visipaque, GE Healthcare) was administered via an antecubital vein to ensure correct timing of the acquisition of contrast-enhanced CCTA images. Once this had been established, a 60 -100 mL bolus of IV contrast was administered at a rate of 5 mL per second, followed by a 20 mL contrast bolus with a 40 mL of saline chaser at a rate of 3 mL per second. All scans were performed with prospective electrocardiographic (ECG) triggering using a 60 -100% phase window, with default image reconstruction at 75% of the R -R cycle length. If this phase was inadequate for accurate coronary reconstruction, other phases were retrospectively reconstructed to achieve maximal quality. Mean effective radiation exposure was derived from the dose-length product multiplied by a conversion coefficient for the chest (k ¼ 0.014 mSv/mGy).
Anonymised CCTA datasets were transferred to a dedicated cardiac workstation (Advantage Workstation version 4.2, GE Healthcare), where image analysis was performed. Two experienced CCTA readers, blinded to both subjects' clinical data and investigation results, used unformatted (raw) axial images, maximum intensity projections, three-dimensional reconstructions, and reformatted multi-planar coronary images to assess for the presence of coronary plaque using a 16-segment model. 19 A third expert reader adjudicated upon segments where disagreement existed. All available coronary segments were assessed, regardless of size. The image quality of each segment was categorized as excellent, suboptimal but diagnostic, or non-diagnostic based on the extent of calcification, motion artefact, and signal-to-noise ratio. Where coronary artery plaque was detected on a per segment basis, it was further evaluated by both the severity of luminal stenosis [minimal (,25%), mild (25-49%), moderate (50 -69%), or severe (≥70%)] and by plaque composition. Non-obstructive plaque was defined as ≤50% luminal narrowing, and obstructive plaque as .50% luminary narrowing. Plaque was characterized as calcified, non-calcified, or mixed ( Figure 1 ). Calcified plaque was defined by any structure distinct from the vessel lumen within the artery wall with a CT attenuation of .130 Hounsfield units (HU), while non-calcified plaque was defined by a structure assigned to the coronary artery wall with CT attenuation above the surrounding tissue but below that of the contrast-enhanced lumen without any calcified plaque being present. 20 Plaque consisting of both calcified and noncalcified elements was classed as mixed. To evaluate overall coronary artery plaque burden, the segment stenosis score (SSS) was derived by totalling the maximum luminal stenosis score for each coronary artery segment [minimal (0 point), mild (1 point), moderate (2 points), and severe (3 points)] to obtain a score ranging from 0 to 48 points. 19 Three separate SSSs were calculated for each patient: for total plaque, for any calcified plaque, and for any non-calcified plaque.
Plasma lipid profiling
Plasma samples (200 mL) were obtained immediately prior to CCTA and stored at 2808C. Plasma samples from the entire cohort in addition to seven quality control samples (pooled plasma from six healthy Plasma lipidomic analysis predicts non-calcified coronary artery plaque in asymptomatic patients individuals) that were evenly spaced within the analytic run were analysed. Total lipid extraction from a 10 mL aliquot of plasma was performed by a single-phase chloroform : methanol (2 : 1) extraction following the addition of one stable isotope or non-physiological internal standard for each lipid class, as described previously. 13 Lipid analysis was performed by liquid chromatography, electrospray ionization-tandem mass spectrometry using a Agilent 1200 liquid chromatography system combined with an Applied Biosystems API 4000 Q/ TRAP mass spectrometer with a turbo-ionspray source (3508C), and Analyst 1.5 data system. Multiple reaction monitoring experiments were used to measure the major species of each lipid class as determined previously. 13 A total of 65 diacylglycerol and triacylglycerol species and 240 other lipid species were analysed in two separate experiments. 13 Relative lipid amounts were calculated by relating the peak area of each species to the peak area of the corresponding internal standard. Total lipid classes were calculated from the sum of the individual lipid species within each class. The major lipid species in the following lipid classes and subclasses were measured: ceramide (Cer), monohexosylceramide (MHC), dihexosylceramide (DHC), trihexosylceramide (THC), G M3 ganglioside (GM3), sphingomyelin (SM), phosphatidylglycerol (PG), phosphatidylinositol (PI), phosphatidylethanolamine (PE), lysophosphatidylethanolamine (LPE), alkylphosphatidylethanolamine (PE(O)), phosphatidylethanolamine plasmalogen (PE(P)), phosphatidylcholine (PC), lysophosphatidylcholine (LPC), alkylphosphatidylcholine (PC(O)), phosphatidylcholine plasmalogen (PC(P)), lysoalkylphosphatidylcholine (LPC(O)), free cholesterol (COH), cholesteryl ester (CE), diacylglycerol (DG), and triaclyglycerol (TG). These abbreviations are only used when referring to individual lipid species as in CE 16 : 1, which defines a cholesteryl ester with a fatty acid containing 16 carbons and 1 double bond. For a number of the lipids which contain two fatty acid chains, the mass spectrometry-based measurements here do not directly determine the constituent fatty acids, but rather the sum of the number of carbons and the sum of the number of double bonds across both fatty acids. Accordingly, we denote these species as the combined length and number of double bonds, for example, PC 32 : 1. It is worth noting, however, that based on previous work by our laboratory and others, the identity of at least the major fatty acids making up such a species in plasma may be reasonably inferred.
Other ancillary markers of CAD
To determine CIMT, carotid ultrasonography was performed by two expert sonographers. Several techniques to evaluate CIMT have been described. 21 In the present study, CIMT was measured (using a 1 cm length) within the first cm proximal to the bifurcation of the common carotid artery. Six mean CIMT measurements were obtained from both the left and right common carotid arteries prior to CCTA, and the overall average was determined for each subject. Offline analysis was performed by two expert readers blinded to CCTA results. Carotidfemoral PWV is an established index of arterial stiffness, an independent predictor of CAD. 5 More recently, brachial-artery PWV (baPWV) has emerged as a simple automated method to assess arterial stiffness, and similar associations with CAD risk and clinical events have been described. 12 baPWV was measured prior to CCTA using a volumeplethymographic device (Colin VP-1000, Omron Healthcare, Lake Forest, USA) that simultaneously recorded PWV, blood pressure, heart sounds, and an ECG. Venous blood sampling to measure hs-CRP levels was performed immediately prior to CCTA.
Statistical analysis
All data are expressed as mean + standard deviation (SD) unless otherwise indicated. We applied covariate-adjusted linear regression to assess the relationship of each of three ancillary markers of CAD (CIMT, baPWV, and hs-CRP) with each of three variants of the SSS (total plaque, any calcified, and any non-calcified). The covariates adjusted for were age, gender, body mass index (BMI), SBP, tobacco use, and statin use. We also applied covariate-adjusted linear regression to assess the relationship of each individual lipid species/lipid class with each of three variants of the SSS. The covariates adjusted for, in this instance, were age, gender, BMI, SBP, tobacco use, statin use, and CIMT. The P-values for linear regression were corrected for multiple comparisons using the Benjamini -Hochberg approach. 22 A corrected P-value of ,0.05 was CCTA, coronary computed tomographic angiography.
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considered to be statistically significant. The beta coefficients obtained relate to the change in the dependent variable associated with an interquartile range increase in the independent variable. Agreement between the two CTCA readers was calculated using Cohen kappa statistics. All analyses were conducted using the Stata software, version 11.1 (StataCorp, College Station, TX, USA) and MATLAB 2012b (MathWorks, MA, USA).
Results
Baseline characteristics
A total of 100 subjects were evaluated during the study period. Clinical characteristics of the study group are presented in Table 1 ; 86% of subjects were male, with a mean age of 61 + 6 years. At enrolment, 80% of subjects had systemic hypertension (defined as blood pressure .140/90 mm Hg or treatment for systemic hypertension), 89% had hypercholesterolaemia (defined as total cholesterol .180 mg/dL or treatment for hypercholesterolaemia), 47% had either previously or currently smoked tobacco, and 43% had a documented family history of symptomatic CAD in a first-degree relative. Only 14% of subjects were prescribed anti-platelet therapy, while approximately one-third were receiving lipid-modifying therapy. At the time of enrolment, the mean Framingham risk score for estimated 10-year risk of MI or coronary death was 12.4 + 6.1%.
CCTA data
CCTA was successfully performed without complication in all 100 subjects. Fifty-six subjects received oral beta-blocker therapy, and IV metoprolol was administered to 29 subjects prior to scanning. Sublingual nitroglycerin was administered to all subjects. All subjects were in sinus rhythm during image acquisition with a mean heart rate of 55 + 6 bpm (range 42-67). The mean effective radiation dose was 5.4 + 2.4 mSv. CCTA results are detailed in Table 2 . Of a total of 1448 coronary segments, 1425 (98%) segments were graded as diagnostic (either 'excellent' or 'suboptimal but diagnostic' image quality) (Figure 2) . The kappa value for interobserver variability for detection of noncalcified plaque was 0.93, indicating excellent agreement. Coronary plaque was identified in 386 (27%) segments, including 61 (4%) segments containing an obstructive stenosis. About 41% of plaques were non-calcified or mixed in composition. Sixteen subjects had no coronary plaque detected, 60 had ≥1 coronary segment with non-obstructive plaque but no segments with obstructive plaque, and 24 had ≥1 coronary segment with obstructive plaque (17 with single-vessel CAD, 3 with double-vessel CAD, and 4 with either triple-vessel CAD or left main CAD) (Figure 3) . Two-thirds of patients exhibited non-calcified plaque.
The SSS for total plaque was 4.6 + 5.0, 4.4 + 4.8 for any calcified plaque, and 2.1 + 3.0 for any non-calcified plaque.
Results of other ancillary markers of CAD
CIMT, baPWV, and hs-CRP measurements were obtained from all subjects. Mean CIMT was 0.72 + 0.15 mm, mean baPWV 1598 + 266 cm/s, and mean hs-CRP level 2.77 + 2.78 mg/L. Following linear regression analysis, none of these ancillary markers of CAD Plasma lipidomic analysis predicts non-calcified coronary artery plaque in asymptomatic patients were found to predict the SSS (total plaque, any calcified plaque, or any non-calcified plaque; Table 3 ).
Plasma lipidomic analysis
After linear regression analysis, 18 lipid species demonstrated significant associations specifically with the SSS (any non-calcified plaque; Table 4 ), but none were significantly associated with the SSS (total plaque) or SSS (any calcified plaque). The GM3 lipid class showed a borderline significant association with the SSS (any non-calcified plaque) [P-value (Benjamini-Hochberg) ¼ 0.050]. With inclusion of CIMT as an additional covariate, 10 lipid species remained significantly associated with the SSS (any non-calcified plaque), and the association with the GM3 lipid class became statistically significant ( Table 5) .
Discussion
To our knowledge, this is the first study to demonstrate a significant association between plasma lipid species and the extent of coronary artery plaque in asymptomatic subjects. These associations were specific for the burden of lipid-rich, non-calcified plaque, which has previously been linked to a heightened risk of acute coronary events. Other contemporary markers of CAD showed no significant relationship with the amount or type of coronary artery plaque. Plasma lipidomic analysis predicts non-calcified coronary artery plaque in asymptomatic patients
In our cohort, 84% of patients manifest coronary artery plaque and 24% had obstructive disease affecting at least one vessel. Despite this high prevalence of CAD, only a minority of patients were receiving anti-platelet or lipid-modifying therapies (14 and 34% of patients, respectively) at the time of CCTA. Conversely, some patients without evidence of coronary plaque had been prescribed these medications. These observations emphasize the need for enhanced risk stratification of this large intermediate risk population. In a retrospective study by Hadamitzky et al., 23 asymptomatic subjects with obstructive CAD by CCTA had a significantly higher rate of the composite endpoint of cardiac death, MI, unstable angina requiring hospitalization, and revascularization after a median duration of follow-up of 27.5 months, than those without obstructive disease. Are all asymptomatic patients with coronary artery plaque by CCTA at higher risk and, therefore, candidates for anti-platelet therapy and aggressive risk factor modification?
In a meta-analysis of patients with suspected CAD, the presence and extent of coronary artery plaque on CCTA, regardless of plaque composition, were independent predictors of adverse cardiovascular events. 24 Min et al. 25 also found that patients undergoing CCTA for the investigation of symptoms had greater all-cause mortality during medium-term follow-up if their SSS for total plaque was .5. In the present study, we also utilized the SSS as an index of plaque burden, and modified it to enable the analysis of plaque burden according to plaque composition. Quantification of calcified coronary artery plaque by the coronary artery calcium (CAC) score is independently associated with increased cardiac risk 26 and has been advocated as a method of re-stratifying asymptomatic patients at intermediate cardiac risk into high-or low-risk groups. 27 However, concern exists that imaging of coronary calcium may identify more chronic, stable lesions than the non-calcified, lipid-rich atherosclerotic plaques that are more vulnerable to sudden rupture and resultant acute coronary syndromes. 28 This has been highlighted by data, suggesting no effect of aggressive preventive therapy based on CAC scoring in reducing future cardiac events. 29 We found that such noncalcified plaque was present in two-thirds of subjects. In a study of patients with suspected CAD who underwent CCTA and follow up for a median 670 days, the number of coronary segments containing any non-calcified plaque was an independent predictor of the composite endpoint of all-cause mortality, non-fatal infarction, and unstable angina. 30 Further CCTA-based longitudinal studies are necessary to better determine whether plaque composition may be comparably as important as the degree of luminal stenosis. While the links between traditional cardiovascular risk factors, including circulating cholesterols and triglycerides, and atherosclerosis have been well studied, novel approaches to detailed metabolic profiling are likely to enhance our understanding and management of cardiovascular diseases. 31 In patients referred for coronary angiography, several amino acid derivatives were independent predictors of mortality. 32 In the present study, several lipid species and the G M3 ganglioside class were independent predictors of non-calcified plaque burden. Of the 18 lipid species associated with non-calcified plaque burden, we have previously reported that 10 of these (including species of phosphatidylcholine, phosphatidylethanolamine, and cholesteryl esters) were associated with stable CAD. 13 Species of each of the six lipid classes (phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, cholesteryl ester, G M3 ganglioside, and diacylglycerol) all contained fatty acids from the de novo lipogenesis pathway (C16 : 0, C16 : 1, C18 : 0, C18 : 1), suggesting an upregulation of de novo lipogenesis may be associated with non-calcified plaque burden. Recent studies examining the association of plasma phospholipid fatty acids with CAD have also found positive associations with fatty acids from the de novo lipogenesis pathway. 33 We have also observed phosphatidylethanolamine and phosphatidylinositol to be positively associated with Type 2 diabetes mellitus, 34 where these metabolic pathways are likely driven by the elevated free fatty acid levels associated with this condition. Overall, these results support the association of lipogenesis and downstream phospholipid metabolic pathways with non-calcified plaque burden. Why were no associations between calcified coronary plaque and plasma lipids observed in the present study? The pathophysiology of atherosclerosis involves: (i) pre-atheroma (i.e. small foci of extracellular lipid deposition); (ii) non-calcified atheroma (with an extracellular lipid core); and (iii) fibroatheroma (with fibrous thickening and calcium deposition). 35 Calcified plaque represents a late stage in coronary atherosclerosis during which dynamic interactions with plasma lipids have likely diminished. This hypothesis is supported by previous research that found reductions in non-calcified, 36 but not calcified, coronary artery plaque following lipid-lowering therapy, and an animal study that demonstrated that marked reductions in blood cholesterol levels had no effect on arterial calcium deposits. demonstrated significant associations with coronary artery plaque burden, and this relationship was specific for non-calcified plaque. CIMT and baPWV do not discriminate between plaque composition and, therefore, their association with non-calcific plaque may be weakened. hs-CRP may better reflect the presence of non-calcified plaque than CIMT and baPWV as low-grade inflammation accompanies atherosclerotic lipid accumulation. However, hs-CRP levels are not specific for plaque inflammation and considerable withinindividual variability exists. A prospective study involving several novel markers of CAD risk in over 1000 asymptomatic participants at intermediate risk of CAD found that CAC score, ankle-brachial index, hs-CRP, and family history were independent predictors of adverse cardiovascular outcomes. 38 In a large cohort study of nearly 6000 asymptomatic subjects, of the 12 newer risk markers for CAD evaluated (including CIMT, PWV, and CRP), only CAC scores and N-terminal fragment of prohormone B-type natriuretic peptide levels improved the accuracy of Framingham risk score predictions. 39 Our findings suggest that plasma lipidomic profiling may assist in identifying those more likely to have 'vulnerable' lipid-rich plaque and, therefore, possibly benefit from more aggressive primary prevention strategies. It remains to be seen whether plasma lipidomic analysis also has prognostic utility in this patient cohort.
Limitations
Owing to the delay between subject registration on the source integrated database registry and recruitment into the present study, a subject's calculated Framingham risk score may have changed in the interim, mainly due to the institution of lipid-modifying therapy.
As only patients at intermediate risk of CAD were evaluated, the generalizability of our findings to other risk groups, including patients with diabetes mellitus, is limited. While coronary artery plaque with a very low CT density (i.e. ,30 HU) has been associated with a greater risk of rupture, 40 we did not specifically assess for this in the present study because, currently, accurate classification of plaque composition by measuring its CT attenuation is not considered to be reliable. 41 Whether plasma lipidomic profiling could be utilized at a population level to improve CAD risk stratification will require the study of a larger cohort of subjects with long-term followup for adverse cardiovascular outcomes.
Conclusions
Plasma lipidomic analysis can predict the burden of non-calcified coronary artery plaque in asymptomatic subjects at intermediate risk of CAD. Given that non-calcified plaque is linked to an increased risk of future acute coronary events, plasma lipid profiling may allow re-stratification of these patients to a higher or lower risk category and, thereby, enable more appropriate and effective primary prevention management strategies.
